NOVYRA PHARMACHEM quarterly results and financials

NOVYRA PHARMACHEM (BSE 519353)₹7.680.00%(6 Nov 2026 close)Tea & Coffee

Key facts

In the Mar 2026 quarter (standalone), NOVYRA PHARMACHEM reported sales of ₹0.09 Cr and net profit of −₹5.33 Cr. For the year to Mar 2026, sales were ₹0.09 Cr and net profit −₹5.36 Cr.

Sales (Mar 2026): ₹0.09 Cr
Net profit (Mar 2026): −₹5.33 Cr
Sales (FY Mar 2026): ₹0.09 Cr
Net profit (FY Mar 2026): −₹5.36 Cr
EPS (Mar 2026): ₹−8.45
Borrowings (Mar 2026): ₹0 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

NOVYRA PHARMACHEM quarterly results

₹ crore unless stated; each column is a quarter.

NOVYRA PHARMACHEM Quarterly results
	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.09
Expenses	0.08	0.06	0.07	0.02	0.03	0.02	0.08	0.04	0.00	0.03	5.44
Operating Profit	−0.02	−0.04	−0.07	0.00	−0.03	0.00	−0.06	−0.04	0.00	−0.01	−5.32
OPM %	−75.0%	—	—	—	—	—	—	—	—	—	−5,330.0%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.04	0.03	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.01	0.00	0.02	0.00	0.00	0.00	0.00
Profit before tax	−0.04	−0.06	−0.07	−0.02	−0.05	−0.02	−0.06	−0.02	0.02	−0.04	−5.35
Tax %	66.8%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net Profit	−0.04	−0.04	−0.05	0.00	−0.03	0.00	−0.04	0.00	0.00	−0.02	−5.33
EPS (Rs)	−0.09	−0.09	−0.10	−0.03	−0.07	−0.03	−0.09	−0.03	0.03	−0.06	−8.45

NOVYRA PHARMACHEM profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

NOVYRA PHARMACHEM Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1.04	1.49	1.72	1.71	0.14	0.14	0.14	0.14	0.00	0.00	0.09	0.09
Expenses	1.01	1.42	1.74	1.83	0.16	0.10	0.18	0.12	0.15	0.09	5.51	5.51
Operating Profit	0.06	0.08	0.00	−0.09	0.00	0.07	−0.01	0.03	−0.15	−0.07	−5.39	−5.37
OPM %	4.8%	6.0%	0.0%	−5.8%	0.0%	40.0%	−13.4%	26.7%	—	—	−5,400.0%	−5,966.7%
Other Income	0.00	0.00	0.00	0.00	0.00	0.06	0.05	0.02	0.00	0.06	0.07	0.07
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.03	0.03	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.00
Profit before tax	0.02	0.06	−0.04	−0.13	−0.03	0.10	0.00	0.04	−0.17	−0.07	−5.38	−5.39
Tax %	100.1%	60.1%	33.4%	0.0%	0.0%	11.2%	0.0%	66.8%	0.0%	0.0%	0.0%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	0.00	0.01	−0.03	−0.12	−0.01	0.07	0.00	0.00	−0.15	−0.05	−5.36	−5.35
EPS (Rs)	0.03	0.04	−0.07	−0.22	−0.04	0.14	0.00	0.03	−0.26	−0.10	−8.49	−8.51
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%	—

NOVYRA PHARMACHEM balance sheet

₹ crore, at each year end.

NOVYRA PHARMACHEM Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6.17	6.17	6.18	6.18	6.18	6.18	6.18	6.18	6.18	6.18	6.31	6.33
Reserves	−0.06	−0.04	−0.02	−0.06	−0.19	−0.20	−0.13	−0.12	−0.11	−0.27	−0.33	−5.73
Borrowings	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.10	0.22	0.42	0.38	0.18	0.08	0.15	0.13	0.16	0.19	0.18	0.87
Total Liabilities	6.21	6.35	6.58	6.50	6.17	6.06	6.20	6.19	6.23	6.10	6.16	1.47
Fixed Assets	4.68	4.82	5.00	4.97	5.02	5.12	5.10	5.09	5.07	5.05	4.92	0.73
CWIP	0.08	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	1.45	1.34	1.58	1.53	1.15	0.94	1.10	1.10	1.16	1.05	1.24	0.74
Inventories	0.00	0.00	0.04	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Trade receivables	0.47	0.54	0.34	0.25	0.16	0.08	0.07	0.09	0.15	0.15	0.07	0.02
Cash & equivalents	0.70	0.65	0.37	0.33	0.17	0.06	0.10	0.07	0.21	0.07	0.25	0.17
Total Assets	6.21	6.35	6.58	6.50	6.17	6.06	6.20	6.19	6.23	6.10	6.16	1.47

NOVYRA PHARMACHEM cash flow

₹ crore, for each year.

NOVYRA PHARMACHEM Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	1.01	0.24	−0.26	−0.03	−0.08	0.00	−0.01	−0.05	0.13	−0.13	−0.27	−3.78
Cash from investing activity	−0.40	−0.30	−0.03	0.00	−0.08	−0.13	0.06	0.04	0.02	0.00	0.19	3.86
Cash from financing activity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.27	−0.14
Net cash flow	0.64	−0.05	−0.29	−0.05	−0.17	−0.12	0.04	−0.04	0.15	−0.15	0.19	−0.10
Capex	1.75	0.36	0.12	0.00	0.08	0.13	0.00	0.02	0.00	0.00	0.00	0.00
Free cash flow	−0.71	−0.09	−0.37	−0.03	−0.15	−0.10	−0.01	−0.06	0.13	−0.13	−0.17	−0.06
CFO / OP %	1,288.0%	520.0%	−267.0%	—	90.0%	—	−17.0%	300.0%	400.0%	100.0%	350.0%	70.0%

NOVYRA PHARMACHEM ratios

Working-capital days and returns, by year.

NOVYRA PHARMACHEM Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	117	184	80	51	32	170	146	195	341	—	—	36
Inventory days	0	0	16	63	0	—	—	—	—	—	—	—
Days payable	—	—	169	259	—	—	—	—	—	—	—	—
Cash conversion cycle	116	183	−72	−144	31	169	145	194	340	—	—	36
Working capital days	93	109	−16	−7	−5	−48	123	147	220	—	—	−1,094
ROCE %	0.9%	0.2%	0.8%	−0.5%	−2.0%	−0.3%	1.5%	0.0%	0.5%	−2.7%	−1.0%	−162.3%

NOVYRA PHARMACHEM: frequently asked questions

What are the latest quarterly results of NOVYRA PHARMACHEM?

For the Mar 2026 quarter, NOVYRA PHARMACHEM reported sales of ₹0.09 Cr and net profit of −₹5.33 Cr. The operating margin was −5,330.0%.

What is the annual revenue of NOVYRA PHARMACHEM?

NOVYRA PHARMACHEM's sales for the year to Mar 2026 were ₹0.09 Cr; over the last twelve months they were ₹0.09 Cr.

What is the net profit of NOVYRA PHARMACHEM?

Net profit for the year to Mar 2026 was −₹5.36 Cr, and −₹5.35 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−8.51.

How much debt does NOVYRA PHARMACHEM have?

NOVYRA PHARMACHEM reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹0.17 Cr.

What is the free cash flow of NOVYRA PHARMACHEM?

Cash from operations was −₹3.78 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.06 Cr.

Loading…